Professor Eva Steiness was the first female Dean at the Faculty of Health Science, University of Copenhagen, she has served as; professor in Clinical Pharmacology in Denmark (Aarhus University), Senior Vice President at Lundbeck AS and as member of the Board of Management. Prof. Steiness, holds an MD and a DSc in Medicine from the University of Copenhagen. In her time at Lundbeck AS, Prof. Steiness created a broad discovery and clinical pipeline including registering and launching Cipramil® (citalopram), an antidepressant drug, that reached blockbuster status. Prof. Steiness later founded Zealand Pharma A/S in 1998. Under Prof. Steiness’ leadership, a GLP-1 agonist (lixisenatide) for the treatment of Type 2 diabetes was developed and licensed to Aventis (Sanofi) in 2003. Lyxumia® (lixisenatide) was first launched into the European market in 2013. Prof. Steiness has held a string of leadership positions among others: Chairman of the Board of Genmab, Member of the Board in several of Lundbeck’s affiliates, Member of the Board of Directors of the Oticon Foundation, Member of the Medical Research Council and Chairman of the Danish Governmental Advisory Board on Research Politics.

Clinical Pharmacology , antidepressant drug,  Cipramil ,Type 2 diabetes